证券日报网讯2月3日，三元生物（301206）在互动平台回答投资者提问时表示，截至2026年1月9日公司 在册股东共15479户。 ...

全文请见 56亿市值三元生物：上市后业绩变脸却豪掷19亿元理财，慷慨分红背后现金管理收益成利润 重要来源！ 三元生物2022年IPO募资总额高达36.86亿元，公司有超20亿元的IPO资金被用于补充流动资金，公司现 金及类现金的资产总计超30亿元，更是有超半数的利润来自于理财收益和利息收入。而三元生物在IPO 前后，多项经营指标发生断崖式变化，IPO募集资金使用也和原计划有较大出入。 近日，市值约56亿元的创业板上市公司三元生物公告拟使用不超过19亿元人民币暂时闲置超募资金进行 现金管理。《每日经济新闻》记者发现，三元生物市值相对较小，却能拿出大笔资金理财并进行大手笔 分红，其背后是公司IPO募集资金带来的现金储备支撑。 ...

每经记者｜闫峰峰 每经编辑｜吴永久 2022年2月，三元生物以109.3元/股发行价登陆创业板，募资总额36.86亿元，募集资金净额35.47亿元， 成为国内赤藓糖醇行业首家上市公司。 然而，与三元生物IPO募资的热度形成鲜明对比的是，公司在上市后股价表现明显偏冷。公司在上市第 二日便破发，其后股价更是持续走弱，一度跌至20.8元。而截至1月26日，公司收盘价为28.21元，较其 前复权后的发行价69.35元仍然大幅破发。 如今三元生物的市值也仅约为56亿元，这对于一个3年多前募资近37亿元的公司来说，在A股也算罕见 了。 三元生物上市后股价表现疲弱，背后是其多项经营指标在上市后的断崖式下跌。 近日，市值约56亿元的创业板上市公司三元生物公告拟使用不超过19亿元人民币暂时闲置超募资金进行 现金管理。《每日经济新闻》记者发现，三元生物市值相对较小，却能拿出大笔资金理财并进行大手笔 分红，其背后是公司IPO募集资金带来的现金储备支撑。 三元生物2022年IPO募资总额高达36.86亿元，公司有超20亿元的IPO资金被用于补充流动资金，公司现 金及类现金的资产总计超30亿元，更是有超半数的利润来自于理财收益和利息收 ...

近日，公司使用暂时闲置超募资金在授权范围内购买了理财产品，现将具体 情况公告如下： | 序 | 发行主体 | 产品名称 | 产品 | 起始日期 | 到期日期 | 赎回金额 | 实际年化 | 收益金额 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 类型 | | | （万元） | 收益率 | （万元） | | | 招商银行 | 招商银行点 | | | | | | | | | 股份有限 | 金系列看涨 | 保本浮 | | | | | | | 1 | 公司滨州 | 两层区间 92 | 动收益 | 2025/10/27 | 2026/01/27 | 2,300.00 | 1.70% | 9.86 | | | 分行 | 天结构性存 | | | | | | | | | 招商银行 | 款 | | | | | | | 一、使用暂时闲置超募资金进行现金管理到期赎回的情况 1 / 4 证券代码：301206 证券简称：三元生物 公告编号：2026-002 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董 ...

证券日报网讯1月23日，三元生物（301206）在互动平台回答投资者提问时表示，截至2026年1月20日公 司在册股东共15644户。 ...

证券代码：301206 证券简称：三元生物 公告编号：2026-001 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时 闲置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超 募资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金 进行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日 起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管 理层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由 公司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超 ...

分红方面，三元生物A股上市后累计派现7.08亿元。近三年，累计派现5.73亿元。 责任编辑：小浪快报 融资方面，三元生物当日融资买入487.91万元。当前融资余额2.73亿元，占流通市值的4.89%，融资余 额低于近一年40%分位水平，处于较低位。 融券方面，三元生物1月22日融券偿还100.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.25万股，融券余额34.66万元，超过近一年90%分位水平，处于高位。 资料显示，山东三元生物科技股份有限公司位于山东省滨州市滨北张富路89号,山东省滨州市滨北梧桐 十路101号，成立日期2007年1月26日，上市日期2022年2月10日，公司主营业务涉及食品添加剂"赤藓糖 醇及其复配产品"的研发、生产和销售。主营业务收入构成为：糖醇类88.22%，功能糖类8.59%，其他 类2.93%，糖苷类0.26%。 截至1月9日，三元生物股东户数1.55万，较上期增加0.76%；人均流通股8416股，较上期减少0.76%。 2025年1月-9月，三元生物实现营业收入4.76亿元，同比减少7.54%；归母净利润6739.87万元，同比减少 16.80% ...

Core Viewpoint - The article discusses the rising interest and potential of D-allohexose (D-阿洛酮糖) as a sugar substitute in the food and beverage industry, highlighting its approval as a new food ingredient and the contrasting dynamics between production and consumer market adoption [1][5][21]. Production Dynamics - Major food and beverage companies are actively seeking to test D-allohexose, which is seen as a promising sugar alternative due to its low caloric content and ability to participate in the Maillard reaction [1][3]. - Following its approval on July 2, 2025, there was a significant surge in market interest, with a 4985% increase in the WeChat index for D-allohexose and notable stock price increases for related companies [1][3]. - Production capacity is rapidly expanding, with companies like Baolingbao and Jinhe Industrial planning to increase their annual production capacities to tens of thousands of tons [9][10][11]. Market Adoption - Despite the production enthusiasm, the consumer market remains relatively quiet, with only a few products incorporating D-allohexose, such as Naixue's tea and a probiotic drink from Youyi C [4][12]. - The slow market adoption is attributed to the lengthy process of product development and the high cost of D-allohexose compared to traditional sugars, which limits its immediate application in consumer products [14][15][21]. Cost and Production Challenges - The cost of D-allohexose remains a significant barrier, with prices ranging from 20,000 to 24,000 yuan per ton, compared to 6,000 yuan for white sugar [15][17]. - The production methods for D-allohexose, including fermentation and enzymatic conversion, present technical challenges that contribute to its higher costs [18][19]. Regulatory and Market Position - D-allohexose is classified as a new food ingredient rather than a food additive, allowing for broader applications across various food categories, unlike other sweeteners that are limited to specific uses [23][26]. - The article suggests that D-allohexose may find its initial applications in high-end markets where consumers are less price-sensitive and more focused on health benefits [21][22].

Core Viewpoint - The increasing health awareness among the public and the deepening "sugar reduction" consciousness have made sugar-free/low-sugar food and beverages mainstream choices, with steviol glycosides emerging as a preferred alternative to sucrose and artificial sweeteners due to their natural, low-calorie, and blood sugar-neutral characteristics. The "Healthy China" strategy and related policies are driving food and beverage companies to adopt natural sweeteners, leading to a projected market size of 1.037 billion yuan for the steviol glycoside industry in China by 2024, representing a year-on-year growth of 10.2% [1][10]. Industry Overview - Steviol glycosides, derived from the Stevia plant, are natural sweeteners with a sweetness level 200-300 times that of sucrose and only 1/300 of its calories, making them suitable substitutes for sugar [2][4]. - The industry has evolved through five stages: introduction, initial industrialization, rapid expansion, adjustment and integration, and high-end upgrading, transitioning from low-end raw material supply to a comprehensive industry chain and high-end product leadership [4][5]. Market Policies - Recent policies emphasize food safety and quality control, including the "14th Five-Year Plan for National Health" and various regulations aimed at optimizing food additive standards, which encourage the use of steviol glycosides and promote a shift towards a more standardized, green, and high-quality industry [6][9]. Industry Chain - The steviol glycoside industry chain includes upstream activities such as the cultivation and harvesting of Stevia, midstream processes like extraction and purification, and downstream applications in food, beverages, health products, pharmaceuticals, and daily chemicals [6][8]. Current Market Demand - The food and beverage sectors are the primary consumers of steviol glycosides, with sugar-free beverages, baked goods, dairy products, and seasonings increasingly incorporating these sweeteners. By 2024, these sectors are expected to account for over 60% of the market [8][10]. Competitive Landscape - The market concentration of the steviol glycoside industry has increased, with leading companies such as Guilin Liyang Biotechnology Co., Ltd. and Chenguang Biotech Group Co., Ltd. dominating the market through technological innovation and comprehensive industry chain strategies [10][11]. Company Analysis - Guilin Liyang Biotechnology Co., Ltd. reported a total revenue of 837 million yuan and a gross profit of 197 million yuan in the first half of 2025, with a gross margin of 23.57% [11]. - Chenguang Biotech Group Co., Ltd. achieved a revenue of 3.658 billion yuan and a gross profit of 507 million yuan in the same period, with a gross margin of 13.86% [11]. Future Development Trends - The industry is expected to focus on high-quality rare components like RebA/RebD/RebM, with a shift from homogeneous price competition to high-end product value competition. There will be a transition from single steviol glycosides to composite products that combine steviol glycosides with other functional ingredients, catering to specific dietary needs [12][13].

（文章来源：证券日报） 证券日报网讯 12月30日，三元生物发布公告称，近日，公司收到容诚会计师事务所（特殊普通合伙） （简称"容诚会计师事务所"）出具的《关于变更山东三元生物科技股份有限公司签字注册会计师的说明 函》。容诚会计师事务所作为公司2025年年度财务报表和内部控制的审计机构，原指派王准女士、郝光 伟先生为项目签字注册会计师，鉴于原签字注册会计师郝光伟先生工作调整，经容诚会计师事务所安 排，将签字注册会计师变更为郑珊杉女士。公司的签字会计师由王准女士、郝光伟先生变更为王准女 士、郑珊杉女士。 ...